III试验-话题@MedSci

#III试验#

3篇内容 | 606人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1941638, encodeId=a1c11941638b0, content=<a href='/topic/show?id=1c6495852f' target=_blank style='color:#2F92EE;'>#III试验#</a>, objectTitle=Blood：III试验：不同方案治疗的骨髓瘤患者的血栓形成情况, objectType=article, longId=195142, objectId=4560195142f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4560195142f2, replyNumber=0, likeNumber=42, createdTime=2020-06-03, rootId=0, userName=wmr111, userId=a8f1167, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4560195142f2, moduleTitle=Blood：III试验：不同方案治疗的骨髓瘤患者的血栓形成情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4560195142f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941637, encodeId=92e6194163e96, content=<a href='/topic/show?id=1c6495852f' target=_blank style='color:#2F92EE;'>#III试验#</a>, objectTitle=罗氏CD20利妥昔单抗治疗寻常型天疱疮的III试验成功, objectType=article, longId=181544, objectId=65631815442f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65631815442f, replyNumber=0, likeNumber=28, createdTime=2020-05-06, rootId=0, userName=wmr111, userId=a8f1167, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65631815442f, moduleTitle=罗氏CD20利妥昔单抗治疗寻常型天疱疮的III试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65631815442f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941636, encodeId=23b0194163694, content=<a href='/topic/show?id=1c6495852f' target=_blank style='color:#2F92EE;'>#III试验#</a>, objectTitle=罗氏的抗病毒药物在PhIII试验中达标, objectType=article, longId=144660, objectId=861e144660de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=861e144660de, replyNumber=0, likeNumber=30, createdTime=2018-08-20, rootId=0, userName=wmr111, userId=a8f1167, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=861e144660de, moduleTitle=罗氏的抗病毒药物在PhIII试验中达标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=861e144660de)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III试验

2020-05-29

wmr111 (审核中...)

前往app查看评论内容

#III试验#

Blood：III试验：不同方案治疗的骨髓瘤患者的血栓形成情况

2020-06-03

wmr111 (审核中...)

前往app查看评论内容

#III试验#

罗氏CD20利妥昔单抗治疗寻常型天疱疮的III试验成功

2020-05-06

wmr111 (审核中...)

前往app查看评论内容

#III试验#

罗氏的抗病毒药物在PhIII试验中达标

2018-08-20

科室
- - 订阅+
  - 更多科室
工具
服务